Market Cap : 427.71 M | Enterprise Value : 327.15 M | PE Ratio : 1.63 | PB Ratio : 6.36 |
---|
ICPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ICPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Intercept Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2023 was -87.99%.
As of today (2023-05-28), Intercept Pharmaceuticals's WACC % is 9.54%. Intercept Pharmaceuticals's ROIC % is -64.80% (calculated using TTM income statement data). Intercept Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for Intercept Pharmaceuticals's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intercept Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's ROIC % distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's ROIC % falls in comparison to its industry or sector. The grey bar indicates the ROIC %'s extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:
ROIC % (A: Dec. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2021 ) | + | Invested Capital (A: Dec. 2022 )) | / count ) |
= | -68.216 * ( 1 - 0% ) | / | ( (98.205 | + | 149.417) | / 2 ) |
= | -68.216 | / | 123.811 | |||
= | -55.10 % |
where
Invested Capital | (A: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 527.023 | - | 88.961 | - | ( 419.689 | - | max(0, 168.161 | - | 508.018 | + | 419.689 | )) |
= | 98.205 |
Invested Capital | (A: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 553.711 | - | 94.244 | - | ( 485.566 | - | max(0, 230.077 | - | 540.127 | + | 485.566 | )) |
= | 149.417 |
Intercept Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2023 is calculated as:
ROIC % (Q: Mar. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2022 ) | + | Invested Capital (Q: Mar. 2023 )) | / count ) |
= | -126.528 * ( 1 - 0% ) | / | ( (149.417 | + | 138.164) | / 2 ) |
= | -126.528 | / | 143.7905 | |||
= | -87.99 % |
where
Invested Capital | (Q: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 553.711 | - | 94.244 | - | ( 485.566 | - | max(0, 230.077 | - | 540.127 | + | 485.566 | )) |
= | 149.417 |
Invested Capital | (Q: Mar. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 504.085 | - | 82.581 | - | ( 433.595 | - | max(0, 207.117 | - | 490.457 | + | 433.595 | )) |
= | 138.164 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Intercept Pharmaceuticals's WACC % is 9.54%. Intercept Pharmaceuticals's ROIC % is -64.80% (calculated using TTM income statement data).
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Saik | officer: EVP & Chief Financial Officer | 640 LEE ROAD, CHESTERBROOK PA 19087 |
M Michelle Berrey | officer: President, R&D and CMO | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
Dagmar Rosa-bjorkeson | director | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Rocco Venezia | officer: Chief Accounting Officer | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001 |
Lisa Defrancesco | officer: SVP, IR & Corp. Affairs | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001 |
Linda M Richardson | officer: EVP & Chief Commercial Officer | 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713 |
Jared Freedberg | officer: General Counsel and Secretary | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Bryan Ball | officer: Chief Quality Officer | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Paolo Fundaro | director, 10 percent owner | C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123 |
Keith Michael Gottesdiener | director | 900 FIFTH AVENUE, #8C, NEW YORK NY 10021 |
Luca Benatti | director | C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011 |
Daniel G Welch | director | 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707 |
Daniel Bradbury | director | BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037 |
Nancy Miller-rich | director | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By GuruFocusNews 07-07-2022
By PurpleRose 08-18-2022
By PurpleRose 07-11-2022
By GuruFocusNews 06-30-2022
By Stock market mentor 01-19-2023
By Value_Insider 11-22-2022
By GlobeNewswire 11-08-2022
Other Sources
By Yahoo Finance 2022-11-01
By tipranks.com 2023-01-19
By Yahoo Finance 2023-01-05
By Yahoo Finance 2022-10-25
By Yahoo Finance 2022-12-23
By Zacks 2023-01-20
By Seekingalpha 2023-01-24
By Yahoo Finance 2022-10-31
By Yahoo Finance 2023-01-20
By Yahoo Finance 2023-01-25
By Yahoo Finance 2022-10-12
By Yahoo Finance 2022-10-26
By Yahoo Finance 2022-11-01
By Yahoo Finance 2022-12-20
By Yahoo Finance 2023-01-13